Loading...
B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes
Costimulatory interactions control T cell activation at sites of activated antigen-presenting cells, including B cells. Blockade of the CD28/CD80/CD86 costimulatory axis with CTLA4Ig (abatacept) is widely used to treat certain autoimmune diseases. While transiently effective in subjects with new-ons...
Na minha lista:
| Udgivet i: | JCI Insight |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Clinical Investigation
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478438/ https://ncbi.nlm.nih.gov/pubmed/30830871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.126136 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|